Patent Ductus ArteriosusPhase 2NCT06152796
Comparision Between Paracetamol and Ibuprofen in Closure of Patent Ductus Arteriosus
A Phase 2 study testing Paracetamol and Ibuprofen in people with Patent Ductus Arteriosus, run by Assiut University.
Trial summary
To compare efficacy and safety of paracetamol and ibuprofen for the pharmacological closure of patent ductus arteriosus (PDA) in preterm infants. Read more about this study
- Who is it for?
- Ages 28 to 37 weeksHealthy volunteers can take part
- Conditions the study is for
- Patent Ductus Arteriosus
- What is being tested?
- Paracetamol and Ibuprofen
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 56 participants
- Where
- No sites listed yet
- Study dates
- 1 Dec 2023to 1 Jan 2026
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 28 to 37 weeks
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- preterm infants
- with gestational age ≤37weeks
- who had echocardiographically confirmed significant PDA.
Who cannot join
- Preterm neonates
- with major congenital anomalies,
- life threatening sepsis,
- NEC,
- IVH,
- urine output <1ml/kg/h in the last 24 h,
Show all 9Show fewer
- serum creatinine concentration >1.5 mg/dl, -platelet count <100,000/ml,
- complex congenital heart,
- or duct-dependent lesions.
Trial locations and contacts
No sites are listed yet.
About this study
Official title: Paracetamol Versus Ibuprofen in Closure of Patent Ductus Arteriosus in Premature Neonates,at Upper Egypt
To compare efficacy and safety of paracetamol and ibuprofen for the pharmacological closure of patent ductus arteriosus (PDA) in preterm infants.
Read the detailed description
The ductus arteriosus (DA) is an essential fetal blood vessel that connects the pulmonary artery to the aorta and serves to shunt blood away from the lungs into the umbilical placental circulation where gas exchange takes place.At birth, closure of the DA is a critical event in the transition to the postnatal circulatory pattern. However, there are situations in which DA closure does not occur or is delayed, resulting in the condition known as persistent patent DA (PDA) .
After birth, it usually closes within 48 h. A persistently PDA is diagnosed when the DA fails to close after 72 h.
PDA accounts for 5% to 10% of all congenital heart diseases. However, the incidence surges up to 60% in preterm infants and is inversely related to gestational age(GA) and birth weight.
The closure of the DA in full-term infants occurs in two steps. Initially, within the first few hours after birth,increased arterial PaO2 and decreased circulating prostaglandins allow the smooth muscle media of the ductus to constrict. As a result of the constriction, the inner muscle wall of the DA develops profound ischemic hypoxia which leads to the formation of vascular endothelial growth factor, transforming growth factor beta,and other inflammatory mediators and growth factors that transform the ductus into a non-contractile ligament.
The clinical consequences of PDA are related to the degree of left- to-right shunting through the PDA, with its associated change in blood flow to the lungs, kidneys, and intestine . This results in increased pulmonary blood flow and increased incidence of further comorbidities such as chronic lung disease, intraventricular hemorrhage(IVH), necrotizing enterocolitis (NEC), and retinopathy.Therefore, closure of the PDA is essential to prevent these complications and to improve both cardiorespiratory status and survival rate .
Clinical criteria of hemodynamically significant PDA (hs-PDA) are the following: tachycardia,bounding pulse with wide pulse pressure, hyperdynamic precordium with continuous murmur on auscultation, hepatomegaly, edema, unexplained metabolic acidosis, failure of respiratory distress syndrome to improve at 2-7 days, and unexplained CO2 retention in mechanically ventilated neonates.
Echocardiography has been examined in multiple studies as an objective measure of hs-PDA.Echocardiographic criteria of hs-PDA are the following: left atrial dilatation (left atrial: aortic root >1.6), diastolic turbulence (backflow) on Doppler in the pulmonary artery, internal diameter of duct >1.5 mm, and reverse end diastolic flow in the descending aorta/mesenteric artery .
Treatment options for hs-PDA include conservative management, pharmacologic interventions, surgical ligation, and a transcatheter approach to ductal closure. However, a consensus on PDA management strategies remains elusive. Surgical ligation is usually considered when other medical treatments have either failed or were contraindicated.
For this purpose, the first-line therapy is medical and nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs of choice, preventing the conversion of arachidonic acid into prostaglandins via cyclooxygenase (COX) inhibition, in both the existing isoforms COX-1 (constitutive) and COX-2 (inducible) . Reduction in prostaglandin levels leads to DA muscular wall constriction through the hypoxia of ductal vasa vasorum and consequent local angiogenesis, formation of neointimal tissue, and apoptosis. These mechanisms, in conjunction with platelet recruitment and activation, lead to processes of obstruction and fibrosis and, as a result, anatomical ductal closure .
Ibuprofen, a non-steroidal anti-inflammatory drug, inhibits both cyclooxygenase-1 and cyclooxygenase-2, which are enzymes necessary for the conversion of arachidonic acid to various prostaglandins among them PGE2.Unlike ibuprofen, paracetamol is thought to act on prostaglandin synthase at the peroxidase region of the enzyme.The role of paracetamol as an alternative treatment for the closure of hsPDA has gained attention because of the potential side-effects of cyclooxygenase inhibitors.
Studies comparing oral paracetamol versus oral ibuprofen in PDA closure reported that oral paracetamol and ibuprofen were similarly effective for the closure of PDA.While,El-Farrash et al. demonstrated that oral paracetamol is an effective and well-tolerated, first line drug treatment of PDA that was comparable to ibuprofen in terms of the rate of ductal closure and even showed decreased LPA, RVSP and LA/Ao ratio.Also,Al-Shaibi et al. documented that oral paracetamol was between cost-effective and dominant over both oral and IV ibuprofen formulations.However, another study done by Roofthooft et al.showed disappointing results with IV paracetamol administration, as PDA closure was reported in only 18% of the patients with relatively low gestational age.
Regarding the drug safety profile,Oncel et al.and Dang et al.reported that both drugs were tolerated and deemed safe in terms of renal and liver variables, as well as a lack of statistically significant difference in major complications(NEC,IVH,bronchopulmonary dysplasia).However,Balachander et al. Revealed Incidence of AKI is significantly lower with paracetamol as compared to ibuprofen.Also, Hammerman et al. reported that paracetamol could offer important therapeutic advantages over NSAIDs (e.g., indomethacin and ibuprofen), as paracetamol has no peripheral vasoconstrictive effect and can be given to infants with clinical contraindications to NSAIDs.
The availability of different management options poses a challenge for neonatologists when making evidence-based management decisions after diagnosing hemodynamically significant PDAs. The dilemma is whether to use pharmacotherapy at all, and if a decision is made to treat the PDA medically, what should be the ideal choice of pharmacotherapy.
- Conditions
- Patent Ductus Arteriosus
- Being tested
- Paracetamol, Ibuprofen
- Medical subject headings
- Ductus Arteriosus, Patent
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
ParacetamolDrug
Anti_inflammatory drug
IbuprofenDrug
Non steroidal anti_inflammatory drug
| Study group | Role | What they receive |
|---|---|---|
| Paracetamol | Experimental | preterms receive oral/iv paracetamol at the dose of 15 mg/kg every 6 h for 3 days. Receives: Drug: Paracetamol |
| Ibuprofen | Experimental | preterms receive oral ibuprofen at the initial dose 10 mg/kg, followed by 5 mg/kg after 24 and 48 h Receives: Drug: Ibuprofen |
What is being measured
The primary outcome is the main question the study is designed to answer.
Closure of PDA
Echo confirmed closure
Measured: 6 days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 Dec 2023
- Study start1 Dec 2023 (estimated)
- Primary completion1 Sep 2025 (estimated)
- Study completion1 Jan 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Patent Ductus ArteriosusStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 56 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nada Abdelfatah Abdelaal Abdelsamie, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06152796
- Sponsor's protocol ID
- closure of PDA
- Status last verified
- Nov 2023
- First submitted
- 15 Nov 2023
- Last updated
- 1 Dec 2023
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 1 Dec 2023. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Paracetamol Versus Ibuprofen in Closure of Patent Ductus Arteriosus in Premature Neonates,at Upper Egypt
- ClinicalTrials.gov ID
- NCT06152796
- Acronym / sponsor ID
- closure of PDA
- Conditions
- Patent Ductus Arteriosus
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 56 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Dec 2023 (estimated)
- Primary completion
- 1 Sep 2025 (estimated)
- Study completion
- 1 Jan 2026 (estimated)
- First posted
- 1 Dec 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To compare efficacy and safety of paracetamol and ibuprofen for the pharmacological closure of patent ductus arteriosus (PDA) in preterm infants.
Detailed description
The ductus arteriosus (DA) is an essential fetal blood vessel that connects the pulmonary artery to the aorta and serves to shunt blood away from the lungs into the umbilical placental circulation where gas exchange takes place.At birth, closure of the DA is a critical event in the transition to the postnatal circulatory pattern. However, there are situations in which DA closure does not occur or is delayed, resulting in the condition known as persistent patent DA (PDA) .
After birth, it usually closes within 48 h. A persistently PDA is diagnosed when the DA fails to close after 72 h.
PDA accounts for 5% to 10% of all congenital heart diseases. However, the incidence surges up to 60% in preterm infants and is inversely related to gestational age(GA) and birth weight.
The closure of the DA in full-term infants occurs in two steps. Initially, within the first few hours after birth,increased arterial PaO2 and decreased circulating prostaglandins allow the smooth muscle media of the ductus to constrict. As a result of the constriction, the inner muscle wall of the DA develops profound ischemic hypoxia which leads to the formation of vascular endothelial growth factor, transforming growth factor beta,and other inflammatory mediators and growth factors that transform the ductus into a non-contractile ligament.
The clinical consequences of PDA are related to the degree of left- to-right shunting through the PDA, with its associated change in blood flow to the lungs, kidneys, and intestine . This results in increased pulmonary blood flow and increased incidence of further comorbidities such as chronic lung disease, intraventricular hemorrhage(IVH), necrotizing enterocolitis (NEC), and retinopathy.Therefore, closure of the PDA is essential to prevent these complications and to improve both cardiorespiratory status and survival rate .
Clinical criteria of hemodynamically significant PDA (hs-PDA) are the following: tachycardia,bounding pulse with wide pulse pressure, hyperdynamic precordium with continuous murmur on auscultation, hepatomegaly, edema, unexplained metabolic acidosis, failure of respiratory distress syndrome to improve at 2-7 days, and unexplained CO2 retention in mechanically ventilated neonates.
Echocardiography has been examined in multiple studies as an objective measure of hs-PDA.Echocardiographic criteria of hs-PDA are the following: left atrial dilatation (left atrial: aortic root >1.6), diastolic turbulence (backflow) on Doppler in the pulmonary artery, internal diameter of duct >1.5 mm, and reverse end diastolic flow in the descending aorta/mesenteric artery .
Treatment options for hs-PDA include conservative management, pharmacologic interventions, surgical ligation, and a transcatheter approach to ductal closure. However, a consensus on PDA management strategies remains elusive. Surgical ligation is usually considered when other medical treatments have either failed or were contraindicated.
For this purpose, the first-line therapy is medical and nonsteroidal anti-inflammatory drugs (NSAIDs) are drugs of choice, preventing the conversion of arachidonic acid into prostaglandins via cyclooxygenase (COX) inhibition, in both the existing isoforms COX-1 (constitutive) and COX-2 (inducible) . Reduction in prostaglandin levels leads to DA muscular wall constriction through the hypoxia of ductal vasa vasorum and consequent local angiogenesis, formation of neointimal tissue, and apoptosis. These mechanisms, in conjunction with platelet recruitment and activation, lead to processes of obstruction and fibrosis and, as a result, anatomical ductal closure .
Ibuprofen, a non-steroidal anti-inflammatory drug, inhibits both cyclooxygenase-1 and cyclooxygenase-2, which are enzymes necessary for the conversion of arachidonic acid to various prostaglandins among them PGE2.Unlike ibuprofen, paracetamol is thought to act on prostaglandin synthase at the peroxidase region of the enzyme.The role of paracetamol as an alternative treatment for the closure of hsPDA has gained attention because of the potential side-effects of cyclooxygenase inhibitors.
Studies comparing oral paracetamol versus oral ibuprofen in PDA closure reported that oral paracetamol and ibuprofen were similarly effective for the closure of PDA.While,El-Farrash et al. demonstrated that oral paracetamol is an effective and well-tolerated, first line drug treatment of PDA that was comparable to ibuprofen in terms of the rate of ductal closure and even showed decreased LPA, RVSP and LA/Ao ratio.Also,Al-Shaibi et al. documented that oral paracetamol was between cost-effective and dominant over both oral and IV ibuprofen formulations.However, another study done by Roofthooft et al.showed disappointing results with IV paracetamol administration, as PDA closure was reported in only 18% of the patients with relatively low gestational age.
Regarding the drug safety profile,Oncel et al.and Dang et al.reported that both drugs were tolerated and deemed safe in terms of renal and liver variables, as well as a lack of statistically significant difference in major complications(NEC,IVH,bronchopulmonary dysplasia).However,Balachander et al. Revealed Incidence of AKI is significantly lower with paracetamol as compared to ibuprofen.Also, Hammerman et al. reported that paracetamol could offer important therapeutic advantages over NSAIDs (e.g., indomethacin and ibuprofen), as paracetamol has no peripheral vasoconstrictive effect and can be given to infants with clinical contraindications to NSAIDs.
The availability of different management options poses a challenge for neonatologists when making evidence-based management decisions after diagnosing hemodynamically significant PDAs. The dilemma is whether to use pharmacotherapy at all, and if a decision is made to treat the PDA medically, what should be the ideal choice of pharmacotherapy.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Paracetamol | Experimental | Drug: Paracetamolpreterms receive oral/iv paracetamol at the dose of 15 mg/kg every 6 h for 3 days. |
| Ibuprofen | Experimental | Drug: Ibuprofenpreterms receive oral ibuprofen at the initial dose 10 mg/kg, followed by 5 mg/kg after 24 and 48 h |
Who may qualify
- Ages
- 28 to 37 weeks
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (3 listed)
- preterm infants
- with gestational age ≤37weeks
- who had echocardiographically confirmed significant PDA.
Key exclusion criteria (9 listed)
- Preterm neonates
- with major congenital anomalies,
- life threatening sepsis,
- NEC,
- IVH,
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| ParacetamolAnti_inflammatory drug | Drug | Paracetamol |
| IbuprofenNon steroidal anti_inflammatory drug | Drug | Ibuprofen |
Primary outcome
Closure of PDA
Time frame: 6 days
Echo confirmed closure
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Dec 2023.
Related trials for Patent Ductus Arteriosus
Recruiting
Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study
Congenital Heart Disease, Congenital Heart Disease (CHD)
Active, not recruiting
PREEMIE: Study for Treatment of PDA in Premature Infants
Patent Ductus Arteriosus (PDA)
Active, not recruitingObservational study
Amplatzer Piccolo Occluder Japan Post-marketing Database Surveillance
Patent Ductus Arteriosus
Active, not recruitingObservational study
PDA for Kidneys Study
Patent Ductus Arteriosus, Congenital Heart Disease
RecruitingPhase 2
Co-administration of Acetaminophen With Ibuprofen to Improve Duct-Related Outcomes in Extremely Premature Infants
Patent Ductus Arteriosus After Premature Birth
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Paracetamol and Ibuprofen in people with Patent Ductus Arteriosus, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 1 Dec 2023. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Nada Abdelfatah Abdelaal (01023085851, nadaabdelfatah4@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Closure of PDA (time frame: 6 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Dec 2023.